PAncreas Borderline and Locally Advanced Snapshot Study
NCT ID: NCT05470738
Last Updated: 2022-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
230 participants
OBSERVATIONAL
2022-09-15
2024-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable
NCT02818907
INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors
NCT04436679
Prospective Monocentric Clinical-biological Database
NCT04136132
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
NCT05546853
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI
NCT05511116
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Patients will be screened by the pancreatic's surgeons practicing in a reference centers during preoperative surgical consultations (V1),
* The patient's non-objection will be sollected,
* The end of follow-up's patient will take place during the post-operative consultation approximately 3 months after surgery (V3)
* Between V1 and V3, preoperative data (demography, history, tumor characteristics, neoadjuvant treatments performed, tumor response), operative, intraoperative, pathological and postoperative data will be collected via a e-CRF " the REDCAP software".
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of pancreatic adenocarcinoma:
* either after cytopuncture with anatomopathological result confirming the diagnosis,
* or with strong suspicion on the combined criterias : clinical, biological and morphological criterion (according to INCa 2019 and NCCN recommendations ) in the event of absence of anatomopathological documentation (failure of several fine needle punctures (maximum 3)/or non-contributory anatomopathological examinations),
* Borderline or locally advanced character depending on the presence of a contact of the tumor with nearby vessels and defined by morphological examination (scanner +/- MRI). These criteria are defined by the NCCN Guidelines for Pancreatic Adenocarcinoma V.1.2021, international reference
Exclusion Criteria
* Patients not operated on for their pancreatic adenocarcinoma,
* Adenocarcinoma of the pancreas operable immediately on diagnosis,
* Metastatic pancreatic adenocarcinoma from the outset on diagnosis,
* Patient without pancreatic adenocarcinoma after histological examination (in the case where the pancreatic lesion was operated on for strong suspicion of pancreatic adenocarcinoma on the combined clinical, biological and morphological criterion (according to INCa 2019 and NCCN recommendations, but that the lesion on definitive pathological examination is not a pancreatic adenocarcinoma)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johan Gagniere
Role: STUDY_DIRECTOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens
Amiens, , France
CHU Besançon
Besançon, , France
CHU Bordeaux
Bordeaux, , France
CHU clermont-ferrand
Clermont-Ferrand, , France
CHU Dijon
Dijon, , France
CHU Lille
Lille, , France
Hospices Civils de Lyon
Lyon, , France
APHM
Marseille, , France
Institut Paoli-Calmettes d'Unicancer
Marseille, , France
CHU Montpellier
Montpellier, , France
CHU Nancy
Nancy, , France
CHU Nantes
Nantes, , France
CHU Nice
Nice, , France
APHP Hopital Beaujon
Paris, , France
APHP Hopital Cochin
Paris, , France
APHP Hopital de la Pitié-Salpétrière
Paris, , France
APHP Hopital Paul Brousse
Paris, , France
CHU Reims
Reims, , France
CHU Rennes
Rennes, , France
CHU Rouen
Rouen, , France
CHU Strasbourg
Strasbourg, , France
CHU Toulouse
Toulouse, , France
CHU Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022 GAGNIERE PALASS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.